PDCD1 and prostate cancer: Compared with the combination treatments of anti‐PD‐1 plus anti‐RANKL antibodies dosed at 100 μg of each antibody (i.e. 200 μg of total antibody), treatment with the anti‐RANKL/PD‐1 BsAb with an equivalent overall antibody dose (200 μg) achieved at least an equivalent improvement in control of RM1 prostate cancer (Figure 2a) or B16F10 melanoma (Figure 2b) lung metastases.